The global collagen vascular diseases market is anticipated to grow at a considerable CAGR of around 7.5% during the forecast period (2021-2027). The key factor to drive the market growth is the increasing prevalence of collagen vascular diseases such as Scleroderma and arthritis. For instance, according to the Journal of Managed Care and Specialty Pharmacy, the prevalence rates of Scleroderma in the US were 15.1 per 100,000 person-years and 25.9 per 100,000 people respectively. Furthermore, according to the Centers for Disease Control and Prevention, in 2040, an estimated 78.4 million US adults aged 18 years and older will have doctor-diagnosed arthritis among them Two-thirds with arthritis will be women. Also, it is estimated that around 34.6 million adults in the US will report arthritis-attributable activity limitations as well in 2040.
Browse the full report description Global Collagen Vascular Diseases Market Size, Share & Trends Analysis Report by Disease Type (Autoimmune Collagen Vascular Diseases and Hereditary Collagen Vascular Diseases), By Diagnostics (Complete Blood Count, Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein, Rheumatoid Factor, and Others (Urinalysis with Microscopic Analysis & Serum Creatinine)), By Therapeutics (Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Antagonists, and Others (Calcium Channel Blockers, PDE-5 Inhibitors & Chelating Agents)), and By End-Users (Hospital & Clinics, Diagnostic Centers, Research Institutes) Forecast, 2021-2027 at https://www.omrglobal.com/industry-reports/collagen-vascular-diseases-market
Rising acquisitions, product approval, collaborations among the major players in the market also propel the growth of the market. For instance, in December 2019, Pfizer Inc announced that the US Food and Drug Administration (FDA) has approved XELJANZ XR for once-daily treatment of patients with moderate to severely active rheumatoid arthritis those who have an inadequate response to methotrexate. With this approval, Pfizer Inc will be able to offer patients and their healthcare providers with moderate to severely active ulcerative colitis a convenient one daily dosing treatment option with Xeljianz.
Market Coverage
o By Disease Type
o By Diagnostics
o By Therapeutics
o By End-User
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Collagen Vascular Diseases Market Report Segment
By Disease Type
1. Autoimmune Collagen Vascular Diseases
2. Hereditary Collagen Vascular Diseases
By Diagnostics
By Therapeutics
By End-Users
Global Collagen Vascular Diseases Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy
@ https://www.omrglobal.com/request-sample/collagen-vascular-diseases-market